Sharemaestro Newsreel

Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings

Biotech company Biogen (BIIB) is set to report its Q2 earnings this Wednesday. Analysts expect a 7.8% year-on-year revenue decline, despite the company exceeding revenue expectations last quarter. While Biogen's stock is down 7.2% in the last month, the broader biotechnology sector has seen …

Johnson & Johnson offers $5.5bn to settle talc cancer lawsuits

Johnson & Johnson has proposed a $5.5 billion settlement to resolve tens of thousands of lawsuits in the United States claiming its talc-based baby powder caused ovarian cancer. This agreement covers nearly all outstanding U.S. cases, though J&J continues to deny a link between …

Johnson & Johnson offers to pay $5.5bn to settle baby powder lawsuits

Johnson & Johnson has offered to pay up to $5.5 billion to resolve tens of thousands of lawsuits alleging that its talc-based baby powder causes ovarian cancer. The company denies the allegations, stating that talc is safe and does not cause cancer, and asserts …

Novartis AG Lobbyists, 2017

This article from OpenSecrets details the lobbyists employed by Novartis AG in 2017, highlighting that out of 84 named lobbyists, 66 (78.6%) had previous federal government experience, including one former member of Congress. It lists the lobbying firms and individual lobbyists working for Novartis, …

Johnson & Johnson Immunology Leader Joins Kymera as Chief Medical Officer

Kymera Therapeutics has appointed Terence Rooney, MD, as its new Chief Medical Officer, succeeding Jared Gollob, MD, who will transition to an advisory role. Dr. Rooney, formerly an immunology leader at Johnson & Johnson, will guide Kymera's global clinical development strategy and advance its …

AstraZeneca PLC 2Q Rev $15.38B

This article provides key financial results for AstraZeneca PLC's second quarter, highlighting revenues of $15.38 billion. The exact details of the earnings, including comparisons to estimates or prior periods, would be expected in the full content.

Merck stock holds its ground as investors await fresh catalysts

Merck & Co. stock is holding steady based on its latest revenue, profit, and guidance, as investors anticipate new catalysts. The company's valuation is anchored by its core prescription portfolio, especially oncology and vaccines, and its development pipeline remains crucial for future growth while …

Bristol-Myers Squibb stock rating held at Market Perform by Raymond James

Raymond James reiterated a Market Perform rating on Bristol-Myers Squibb (NYSE:BMY), stating that recent ZEPHYR trial data for ML-007C-MA does not pose a risk to Cobenfy and confirms its strong position in schizophrenia treatment. The firm believes Cobenfy has a significant commercial and clinical …

Sun Pharma to acquire US-based Organon in nearly $11.75 billion deal

India's Sun Pharmaceutical Industries announced its largest overseas acquisition to date, an all-cash deal to buy New York-listed Organon & Co for $11.75 billion. This acquisition will expand Sun Pharma's innovative medicines business, strengthen its presence in established brands and generics, and enable its …

Biogen Q2 2026 Earnings Preview — July 29, Street Expects $2.10 EPS

Wall Street anticipates a significant earnings decline for Biogen Inc. in its second-quarter 2026 results, with analysts expecting $2.10 EPS on July 29th. This forecast represents a 61.6% year-over-year EPS drop and a 7.2% revenue contraction, reflecting substantial uncertainty and a sharp deterioration in …

AstraZeneca’s MONTEROSA Study Tracks Real World Outcomes for STRIDE in Liver Cancer

AstraZeneca has announced an update on its MONTEROSA study, which tracks the real-world use of its STRIDE regimen (tremelimumab and durvalumab) for liver cancer across Italian centers. The observational study aims to assess patient progression to serious liver problems, quality of life, and the …

MRK|Merck & Co Inc|Price:130.770|Chg%:-0.300

Merck & Co Inc (MRK) exhibits stable fundamentals and high growth potential, with its valuation considered fairly valued within the Pharmaceuticals industry. Analysts have rated it as "Buy" with a target price of 132.45 over the past month. The company is a high dividend …

Biogen Inc. stock underperforms Monday when compared to competitors

Shares of Biogen Inc. (BIIB) fell 1.01% on Monday, closing at $200.14, despite a positive trading session for the broader stock market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains, highlighting Biogen's underperformance compared to its competitors. This decline …

Bristol Myers Squibb (NYSE:BMY) Reaches New 52-Week High - Should You Buy?

Bristol Myers Squibb (NYSE:BMY) recently hit a new 52-week high of $63.24, trading around $63.07, and has a market capitalization of approximately $128.1 billion. Analyst sentiment is mixed, with 8 buys, 10 holds, and 1 sell rating, and an average price target of $61.25, …

AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus

AstraZeneca's push for "Chinese speed" and ambitious 2030 sales goals are intensifying scrutiny on the pharmaceutical and biotech sectors. This article highlights Krystal Biotech, TG Therapeutics, and Gilead Sciences as examples of companies whose trajectories are particularly exposed to these industry-wide shifts. It details …

Bristol Myers Squibb launches Relopduo, its fixed-dose combination for skin cancer, in India

Bristol Myers Squibb (BMS) has launched Relopduo, a fixed-dose combination for unresectable or metastatic melanoma, in India. This drug, which combines nivolumab and relatlimab, is the first FDA-approved FDC of two immune checkpoint inhibitors. Priced at ₹2,99,900 per vial, it offers a new treatment …

Construction begins on Eli Lilly's $6.5B manufacturing campus in Generation Park

Eli Lilly has started construction on several projects for its $6.5 billion, 236-acre manufacturing campus in Humble, Texas's Generation Park, with some work expected to be completed by late 2027 and the overall project by 2030. The site will produce Orforglipron, a GLP-1 medication …

Quantinuum, NVIDIA Corporation, and Pfizer Inc Transformer Models Now Generate Quantum Circuits for Molecular Models

Researchers from Quantinuum, NVIDIA Corporation, and Pfizer Inc. have developed ADAPT-GQE, a generative AI framework that significantly speeds up the creation of quantum circuits for complex molecular modeling. This new approach reduces circuit generation time by an order of magnitude compared to ADAPT-VQE, while …

Theo Ai Strengthens Governance With Appointment of Former Bristol Myers Squibb GC to Board

Theo Ai has appointed Sandra Leung, former Executive Vice President and General Counsel of Bristol Myers Squibb, to its Board of Directors, enhancing the company's governance and strategic direction. Leung's extensive experience in litigation, corporate governance, and risk management will help tailor Theo Ai's …

Theo Ai Appoints Former Bristol Myers Squibb General Counsel Sandra Leung to Board

Theo Ai has appointed Sandra Leung, former EVP and General Counsel of Bristol Myers Squibb, to its board of directors. Leung previously served on Theo Ai’s General Counsel Advisory Board and brings over 30 years of corporate legal experience, including expertise in litigation risk …

Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter

Sarepta Therapeutics has appointed Michael Severino, former vice chairman at AbbVie and CEO of Tessera Therapeutics, as its new chief executive, effective Tuesday. Severino replaces Doug Ingram, who is retiring due to family health issues. Severino will face the challenge of navigating commercial realities …

Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO

Sarepta Therapeutics has appointed Michael Severino, an executive with experience at AbbVie and Amgen and most recently Tessera Therapeutics, as its new CEO, effective July 28. Severino faces the challenge of turning around Sarepta's fortunes, as the company has lost significant market value over …

Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Pfizer Japan Inc. and Eisai Co., Ltd. announced a co-promotion agreement for Nurtec® OD Tablet 75mg (rimegepant sulfate hydrate) in Japan, starting September 1, 2026. Nurtec is an oral CGRP receptor antagonist used for both acute treatment and prophylaxis of migraine. This collaboration aims …

Scilex Holding Co (SCLX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Scilex Holding Co (SCLX), listing both major shareholders and institutional holdings. It provides a breakdown of shareholder types, including corporations, hedge funds, and investment advisors, along with the proportion of shares held by each. The data also …

Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis

Mira Pharmaceuticals Inc (MIRA) currently holds a financial score of 7.04, ranking 155 out of 386 in the Biotechnology & Medical Research industry, indicating a robust financial status despite low operating efficiency. The report highlights various financial and operational metrics, such as Quality of …

(BIIB) Volatility Zones as Tactical Triggers

This article analyzes Biogen Inc. (NASDAQ: BIIB), highlighting weak near and mid-term sentiment despite a positive long-term outlook. It presents AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide investors. The report details specific entry, target, …

Sarepta names former AbbVie R&D exec Michael Severino as next CEO

Sarepta Therapeutics has appointed Michael Severino, formerly of Tessera Therapeutics and AbbVie, as its new CEO, succeeding Doug Ingram. Severino takes the helm at a critical juncture as Sarepta awaits two key FDA decisions for its Duchenne muscular dystrophy drugs, Amondys 45 and Vyondys …

AstraZeneca drug prices evolving in response to Trump policy, executive says

AstraZeneca is adjusting its pricing strategy for new drug launches in response to former U.S. President Donald Trump's "most-favoured-nation" policy, which aims to lower drug prices for Americans. This policy links U.S. medicine prices to those in other wealthy countries, intensifying pressure on European …

AbbVie stock hits all-time high of 261.71 USD

AbbVie Inc. (ABBV) stock has reached a new all-time high of $261.71, reflecting a 40.53% total return over the past year. Despite being considered slightly overvalued by InvestingPro analysis, the company demonstrates strong financial health with 9.5% revenue growth. Upcoming earnings on July 31st …

Novartis AG Lobbyists, 2022

This article from OpenSecrets details the lobbyists working for Novartis AG in 2022, including information on their hiring firms and whether they are part of the "revolving door" of former government employees. It lists 60 named lobbyists, with 47 (78.3%) having previous federal government …

TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $180

TD Cowen has reiterated its Hold rating on Novartis AG (NVS.US) and maintained its price target of $180. This indicates an analyst's view that the stock is expected to perform in line with the market, with the current valuation justifying the existing price.

Medicus Pharma Ltd (MDCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

Is AbbVie Stock a Buy After Its $10.9 Billion Apogee Bet

AbbVie (ABBV) recently acquired Apogee Therapeutics for $10.9 billion, a move that is expected to dilute adjusted EPS until 2032 but aims for a "mega blockbuster" drug, zumilokibart, targeting over $10 billion in peak sales. Despite the near-term dilution, AbbVie stock has largely recovered …

Sarepta names former Abbvie president as CEO as Ingram retires

Sarepta Therapeutics has appointed Michael Severino, former Tessera Therapeutics CEO and a longtime AbbVie executive, as its new chief executive, effective July 28. Severino will succeed Doug Ingram, who is stepping down after leading Sarepta since 2017 but will remain in an advisory role …

BMO reiterates Bristol-Myers Squibb stock rating on Cobenfy edge By Investing.com

BMO Capital has reiterated its Market Perform rating and $60.00 price target for Bristol-Myers Squibb (NYSE: BMY), citing the competitive advantage of its schizophrenia drug, Cobenfy. This follows a failed Phase 2 trial for a competing drug, ML-007C-MA, which did not meet statistical significance. …

How Abbvie Inc. (ABBV) Affects Rotational Strategy Timing

This article from Stock Traders Daily analyzes Abbvie Inc. (ABBV) and its impact on rotational strategy timing. It highlights a neutral sentiment for ABBV across all horizons, suggesting a wait-and-see approach, and identifies no resistance levels above the current price, indicating potential upside. The …